Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs

Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women . This study will evaluate the immunogenicity and the safety of the HPV vaccine in female subjects aged 10 - 14 years in Korea.

Study participants will receive either HPV or hepatitis A vaccine, study duration will last for 7 months and involve a total of 4 visits.

Inclusion criteria:

• A female subject between, and including, 10 and 14 years of age at the time of the first vaccination.
• Written informed assent from the subject and informed consent from the parent or guardian of the subject should be obtained prior to enrolment.
• Subjects must have a negative urine pregnancy test.
• Healthy subject before entering the study as established by medical history and clinical examination.
• Subject must be of non-childbearing potential.

Exclusion criteria:

• Pregnant or breastfeeding.
• Previous vaccination against HPV.
• Known acute or chronic, clinically significant neurologic, hepatic or renal functional abnormality
• History of chronic condition(s) requiring treatment such as cancer, chronic hepatic or kidney disease(s), diabetes, or autoimmune disease."